Cost-effectiveness of utidelone and capecitabine versus monotherapy in anthracycline- and taxane-refractory metastatic breast cancer
BackgroundThis study aimed to assess the cost-effectiveness of combining utidelone with capecitabine, compared to capecitabine monotherapy, for the treatment of anthracycline- and taxane-refractory metastatic breast cancer within the Chinese healthcare system.MethodsA partitioned survival model was...
Сохранить в:
| Главные авторы: | , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Frontiers Media S.A.
2024-07-01
|
| Серии: | Frontiers in Pharmacology |
| Предметы: | |
| Online-ссылка: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1303808/full |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|